Drug Discovery World

FEBRUARY 8, 2023

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Takeda’s vaccine candidate Qdenga for active immunisation against dengue infection from four years of age. The post UK approval for dengue virus vaccine candidate appeared first on Drug Discovery World (DDW).

Virus 130

Virus Vaccine Trials Production 130

Drug Discovery World

SEPTEMBER 15, 2023

Replicate Bioscience has dosed the first participant in a Phase I trial of its RBI-4000 vaccine for the prevention of rabies. Rabies, RBI-4000 and the Phase I trial Rabies remains a public health threat in several geographical regions and is designated an NIAID Priority Pathogen.

Vaccine 130

Vaccine Trials Immune Response Virus 130

Drug Discovery World

MAY 23, 2024

A team of scientists in the US and the UK are combining a genetically modified cold sore virus with a cancer vaccine to treat an aggressive type of brain cancer in children. The researchers will use a genetically engineered herpes simplex virus type 1 to eliminate cancer cells. million of funding for this research project.

Virus 147

Virus Immune Response Vaccine Engineering 147

Drug Discovery World

MAY 18, 2023

A clinical trial of an experimental universal influenza vaccine developed by researchers at the National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center (VRC) has begun enrolling volunteers at Duke University in Durham, North Carolina. The trial will enrol up to 50 healthy volunteers aged 18 to 49.

Clinical Trials 130

Clinical Trials Vaccine Trials Immune Response 130

Drug Discovery World

SEPTEMBER 18, 2023

Next generation Covid-19 vaccines could have the potential to expand the breadth of coverage against existing and future variants of the virus, extend the duration of protection, and offer better protection in the prevention of illness and transmission over the current state of vaccine technologies.

Clinical Trials 130

Clinical Trials Vaccine Trials Government 130

Drug Discovery World

MARCH 30, 2023

Likang Life Sciences has been granted implied approval by China’s National Medical Products Administration (NMPA) for the clinical trial of its innovative personalised neoantigen-targeted vaccine LK101 Injection for advanced solid tumours. Vaccines predicated on neoantigens therefore elicit truly tumour-specific T cell responses.

Vaccine 130

Vaccine Regulations Trials Immune Response 130

Drugs.com

AUGUST 1, 2024

1, 2024 -- A next-generation nasal vaccine for COVID-19 appears to do what injectable vaccines can’t -- actually stop the spread of the virus from person to person.Hamsters that received the nasal vaccine didn’t pass the virus on to. THURSDAY, Aug.

Vaccine 110

Vaccine Trials Virus 110

Drug Discovery World

DECEMBER 6, 2022

While scientists have struggled in the past to create an effective vaccine against HIV, a novel vaccine design strategy shows new promise, according to data from a first-in-human clinical trial. . The Phase I trial (IAVI G001) tested the first stage in a multi-stage HIV vaccine regimen the researchers are developing.

Vaccine 130

Vaccine Trials Clinical Trials Virus 130

Drug Discovery World

JUNE 10, 2024

The US Food and Drug Administration (FDA) has approved mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection. This approval is also the first time an mRNA vaccine has been approved for a disease other than Covid-19.”

Vaccine 147

Vaccine FDA Approval FDA Virus 147

Drugs.com

SEPTEMBER 4, 2024

4, 2024 -- Current vaccines against mpox were designed to fight an older, rarer cousin of the virus, smallpox.Now, new research from the drug company Moderna suggests its new mpox vaccine, based on mRNA technology, might do a. WEDNESDAY, Sept.

Vaccine 98

Vaccine Trials Virus Research 98

Drug Discovery World

FEBRUARY 19, 2024

Replicate Bioscience has shared positive results from the Phase I trial of RBI-4000, its srRNA-based rabies vaccine. In this clinical trial, evaluating safety and immunogenicity of RBI-4000 , participants received one or two doses of srRNA vaccine at low doses (0.1mcg, 1mcg or 10mcg).

Vaccine 130

Vaccine Immune Response RNA Virus 130

Drug Discovery World

APRIL 15, 2024

Naobios has signed a partnership agreement with Sumagen, a Korean-Canadian biotechnology company developing an HIV-1 vaccine candidate, to manage the manufacturing process during its Phase II clinical trials. At the end of 2022, the World Health Organization (WHO) reported that approximately 39 million people were living with HIV.

Vaccine 130

Vaccine Clinical Trials Trials Virus 130

Drug Discovery World

AUGUST 7, 2024

The US Food and Drug Administration (FDA) has cleared GigaGen’s application to initiate a Phase I trial of its polyclonal drug for the treatment of hepatitis B virus (HBV) infection, GIGA-2339. It is the first recombinant polyclonal therapeutic in development to treat and functionally cure chronic HBV infection.

Drug Trials 147

Drug Trials FDA Trials Immune Response 147

Drug Discovery World

MAY 15, 2024

Researchers have developed a new vaccine technology that can provide protection against a broad range of coronaviruses with potential for future disease outbreaks – including ones we don’t know about yet. By training the immune system to attack these regions, it gives protection against other coronaviruses not represented in the vaccine.

Vaccine 130

Vaccine Immune Response Clinical Trials Virus 130

Drug Discovery World

JUNE 6, 2024

Cancer vaccine mRNA-4157 (V940) in combination with Keytruda reduced the risk of recurrence or death by 49% in patients with resected high-risk melanoma, according to follow-up data presented at ASCO 2024. Ultimately it will contribute to survival rates improving continually over the next decades and more.” months after initial treatment.

Vaccine 147

Vaccine Clinical Trials FDA Approval Research Laboratories 147

Drug Discovery World

OCTOBER 27, 2023

HB-400, a novel arenaviral therapeutic vaccine developed by HOOKIPA Pharma and Gilead Sciences, has been shown to generate robust T cell responses specific to hepatitis B virus with high antibody levels in a preclinical setting. A Phase I clinical trial to evaluate the safety and tolerability of HB‑400 in humans is ongoing.

Vaccine 130

Vaccine Immune Response Virus Clinical Trials 130

Drug Discovery World

JULY 19, 2022

An early-stage clinical trial has been launched in the US investigating a vaccine against Nipah virus infection. . The clinical trial has been launched by the National Institute of Allergy and Infectious Diseases (NIAID) to evaluate an investigational vaccine to prevent infection with Nipah virus.

Clinical Trials 130

Clinical Trials Trials Virus Vaccine 130

Drug Discovery World

MARCH 15, 2024

Valneva Scotland is focused on vaccines for infectious diseases with significant unmet medical needs. The company’s vaccine for Chikungunya virus (IXCHIQ) was approved by the US Food and Drug Administration (FDA) in November 2023 and is the world’s first and only vaccine for Chikungunya.

Vaccine 147

Vaccine Science Clinical Trials Virus 147

Drug Discovery World

FEBRUARY 23, 2023

Covid-19 booster candidate UB-612 has achieved its immunogenicity endpoints in a head-to-head trial against three vaccine platforms: mRNA (Pfizer-BioNTech’s BNT162b2), adenovirus vector (AstraZeneca’s ChAdOx1-S), and inactivated virus (Sinopharm’s BIBP).

Vaccine 130

Vaccine Immune Response Virus Clinical Trials 130

Drug Discovery World

DECEMBER 18, 2023

An effective HIV vaccine may need to prompt strong responses from CD8+ T cells to protect people from acquiring HIV, according to a study from the National Institute of Allergy and Infectious Diseases (NIAID). Further tests revealed that this dampened response was due to reduced sensitivity to HIV of vaccine recipients’ T-cell receptors.

Vaccine 147

Vaccine Clinical Trials Laboratories Virus 147

Drug Discovery World

AUGUST 7, 2023

A new Vaccine Development and Evaluation Centre (VDEC) has been unveiled in the UK, with the aim of building on the UK’s pandemic legacy and helping develop life-saving new vaccines that will fight ‘ Disease X ‘, a term used because what might trigger the next pandemic is unknown.

Vaccine 130

Vaccine Virus Clinical Trials Disease 130

Drug Discovery World

AUGUST 3, 2023

It becomes the ninth Covid-19 vaccine to be authorised by the UK’s independent medicines regulator. Bimervax combines a part of the SARS-CoV-2 virus spike protein with an adjuvant. The vaccine demonstrated a strong immune response, and the most common side effects were mild, and self-resolved within a few days of vaccination.

Vaccine 130

Vaccine Immune Response Clinical Trials Virus 130

Drug Discovery World

AUGUST 23, 2023

The US Food and Drug Administration (FDA) has approved the first vaccine for pregnant individuals to prevent respiratory syncytial virus (RSV) in infants. In infants and children, the risk of RSV-associated LRTD is highest during the first year of life.

FDA Approval 130

FDA Approval Vaccine FDA Virus 130

Drug Discovery World

NOVEMBER 30, 2022

The University of Queensland is set to take a second-generation molecular clamp vaccine to a proof-of-concept human trial. . The synthetic antigen can then be purified and rapidly manufactured into a vaccine. . The post Clamp2 provides vaccine hope for future pandemics appeared first on Drug Discovery World (DDW).

Vaccine 130

Vaccine Immune Response Virus Engineering 130

Drug Discovery World

JULY 12, 2024

Clinical trial news has caught our attention this week. Despite the revelation from Phesi that a third of clinical trials fail at Phase II, DDW has reported positive human trial updates on therapeutics for myasthenia gravis, non-small cell lung cancer, Marburg virus, and Parkinson’s disease. Mission awarded $5.2m

Clinical Trials 130

Clinical Trials Virus Trials Vaccine 130

Drug Discovery World

AUGUST 9, 2023

A new respiratory syncytial virus (RSV) vaccine candidate has achieved positive safety and immunogenicity results in a Phase I clinical study of RSV-naïve participants between the ages of six and 36 months. MV-012-968 is being developed by Meissa Vaccines as a needle-free, adjuvant-free vaccine to protect infants and toddlers from RSV.

Vaccine 130

Vaccine Virus Disease Drugs 130

Drug Discovery World

DECEMBER 22, 2022

Potential new drug candidates have been identified by a respiratory syncytial virus (RSV) artificial intelligence programme, as health officials warn of a “tripledemic” of SARS-CoV-2, influenza and RSV. . The post AI identifies drug candidates for respiratory syncytial virus appeared first on Drug Discovery World (DDW).

Virus 130

Virus Clinical Trials Drugs Hospitals 130

DrugBank

JULY 18, 2024

Vaccines have consistently demonstrated their efficacy in protecting people from infectious diseases. Yet, the recent COVID-19 pandemic highlighted the obstacles that are inherent today in the development of vaccines. Stabilizers play a crucial role in maintaining the vaccine's potency and integrity throughout its shelf life.

Vaccine 79

Vaccine Immune Response Clinical Trials Virus 79

Drug Discovery World

SEPTEMBER 22, 2023

As we approach another autumn/winter season in the northern hemisphere, Covid-19 vaccines are once again making the headlines, but in the last week we have also reported on vaccine trials for a number of other conditions, including Nipah virus, rabies and lung cancer.

Vaccine 130

Vaccine Clinical Trials Virus Drugs 130

Drug Discovery World

SEPTEMBER 25, 2023

As we approach another autumn/winter season in the northern hemisphere, Covid-19 vaccines are once again making the headlines, but in the last week we have also reported on vaccine trials for a number of other conditions, including Nipah virus, rabies and lung cancer.

Vaccine 147

Vaccine Virus Trials Drugs 147

The Pharma Data

JUNE 7, 2023

This is the first time an RSV vaccine for older adults has been granted European Marketing Authorisation. This authorisation for Arexvy means eligible adults can be vaccinated against RSV disease for the first time, reinforcing GSK’s long history of vaccine innovation. The vaccine was generally well tolerated.

Virus 40

Virus Vaccine Disease Trials 40

The Pharma Data

AUGUST 13, 2020

The UK government has signed deals for a further 90 million doses of coronavirus vaccine. The vaccines are being developed by the Belgian pharmaceutical company Janssen and the US biotech company Novavax. It means the UK has placed orders for six experimental vaccines, taking its potential stockpile to 340 million doses.

Vaccine 52

Vaccine Virus Government Clinical Trials 52

Drug Discovery World

OCTOBER 27, 2023

My news highlights this week feature a variety of treatment approaches, from cell therapy and antibody-drug conjugate to autotaxin inhibitor and arenaviral vaccine, all entering early in-human clinical trials to treat a range of diseases.

Vaccine 130

Vaccine Drugs Therapies Clinical Trials 130

The Pharma Data

SEPTEMBER 14, 2020

. AstraZeneca has confirmed that clinical trials assessing its Oxford University partnered coronavirus vaccine AZD1222 have resumed in the UK, following a green light by the Medicines Health Regulatory Authority (MHRA). Source link. Source link.

Vaccine 52

Vaccine Trials Immune Response Virus 52

The Pharma Data

APRIL 27, 2023

This is the first time an RSV vaccine candidate for adults has gained a positive opinion, one of the final steps in the marketing authorisation procedure prior to approval by the European Commission. There are no RSV vaccines or specific treatments currently available for older adults. Efficacy was 94.6% (95% CI, 65.9–99.9,

Virus 40

Virus Vaccine Trials Clinical Trials 40

Drug Discovery World

MAY 17, 2024

From a weight loss drug that prevents heart attacks and a gene therapy that restores hearing, to a vaccine that can treat viruses that don’t exist yet, our chosen news stories this week all represent potential breakthroughs in their respective fields. News round-up for 13-16 May by DDW Senior Digital Content Editor Diana Spencer.

Therapies 130

Therapies Vaccine RNA Clinical Trials 130

The Pharma Data

SEPTEMBER 25, 2020

A trial of a new vaccine that appears to train the immune system to fight coronavirus has begun in the UK. Early tests showed the jab, developed by US biotechnology company Novavax, leads to high levels of virus-fighting antibodies being produced. The vaccine has been tested in animals and small numbers of people already.

Vaccine 52

Vaccine Trials Immune Response Virus 52